Although targeting mTOR signaling may be expected to exhibit potent antitumor immunomodulatory effects in cancer therapy, one of the critical issues is how rapamycin can be utilized to maximize treatment benefits and improve therapeutic efficacy in novel combinations. Here, MTOR is linked to cancer.